SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories launches 'Empanorm' medicine in India

12 Mar 2025 Evaluate

Alkem Laboratories has launched generic empagliflozin and its combinations in India under the brand name ‘Empanorm’ at prices that are around 80% lower than the innovator products. Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). The company’s generic empagliflozin and its combinations are bioequivalent to innovator products. 

Keeping patient-convenience in mind, the company is offering the medicine in a considerably smaller tablet size than the innovator products. The company’s generic empagliflozin is available under the brand name ‘Empanorm’ and its combinations namely empagliflozin and linagliptin is available under the name ‘Empanorm L’; empagliflozin and sitagliptin is available under the name ‘Empanorm Duo’ and ‘Alsita E’; and empagliflozin and metformin is available under the name ‘Empanorm M’.

Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×